UNITED ~~STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549~~STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) ~~of the Securities Exchange Act of 1934~~

~~Date~~ of ~~Report~~the ~~(Date~~Securities ofExchange ~~earliest~~Act ~~event~~of ~~reported): March 10, 2023~~1934

~~TCR2~~Date ~~Therapeutics~~of ~~Inc.~~Report (Date of earliest event reported):

~~(Exact~~March ~~name~~23, ~~of Registrant as Specified in Its Charter)~~2023

Delaware	001-38811	47-4152751
(State or Other Jurisdictionof Incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)
100 Binney StreetSuite 710
Cambridge, Massachusetts		02142
(Address of Principal Executive Offices)		(Zip Code)

TCR2 THERAPEUTICS INC.

~~Registrant’s~~(Exact ~~Telephone~~name ~~Number,~~of ~~Including~~registrant ~~Area~~as ~~Code:~~specified ~~617~~in ~~949-5200~~its charter)


Delaware	001-38811	47-4152751
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S Employer Identification No.)


100 Binney Street	Suite 710	Cambridge	MA	02142
	(Address of Principal Executive Offices)			(Zip Code)

(617) 949-5200

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		TradingSymbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 Par Value		TCRR		The Nasdaq Stock Market LLC


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	TCRR	The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 72.~~01 Regulation~~02 FDResults ~~Disclosure.~~of Operations and Financial Condition

On March 23, 2023, TCR2 Therapeutics Inc. ~~(the~~announced ~~“Company”) informs~~ its ~~investors~~financial ~~that~~results itfor ~~has~~the ~~less~~fiscal ~~than~~quarter ~~$0.1~~ended ~~million~~December ~~of unrestricted cash~~31, ~~cash~~2022. ~~equivalents~~The ~~and~~full ~~investments~~text ~~held~~of atthe ~~Silicon~~press ~~Valley~~release ~~Bank.~~issued ~~The~~in ~~Company~~connection ~~has~~with ~~approximately~~the ~~$1.2~~announcement ~~million~~is offurnished ~~restricted cash~~ as ~~certificates~~Exhibit of99.1 ~~deposits~~to ~~for~~this ~~facility~~Current ~~leases~~Report ~~held~~on atForm ~~Silicon Valley Bank~~8-K.

The information ~~contained~~ in this ~~Item~~Report 7on Form 8-K, including Exhibit 99.011, attached hereto is ~~being~~intended to be furnished and shall not be deemed “filed” for ~~the~~ purposes of Section 18 of the Securities Exchange Act of 1934, ~~as amended~~ (the “Exchange Act”), or otherwise subject to the liabilities of that section., ~~The~~nor ~~information in this Item 7.01~~ shall ~~not~~it be deemed incorporated by reference ~~into~~in any filing under the Securities Act of 1933, ~~as amended,~~ or the Exchange Act, except as expressly set forth by specific reference in such filing.

~~Forward-Looking~~Item 9.01 Financial Statements and Exhibits.

~~This~~(d) Current Report on Form 8-K contains forward-looking statements of the Company that involve substantial risks and uncertainties. Any statements in this Form 8-K about the Company’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include any express or implied statements about the Company’s strategy, operations and future expectations and plans and prospects for the Company, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “seek,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. In this Form 8-K, the Company’s forward looking statements include statements about its cash, cash equivalents and available for sale securities balances, banking relationships and needs for additional financing. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s financial and operating results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including the factors discussed in the “Risk Factors” section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company’s views only as of the date of this Form 8-K. The Company anticipates that subsequent events and developments may cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law.Exhibits

SIGNATURES


Exhibit No.		Description
99.1		Press release dated March 23, 2023
104		Inline XBRL cover page

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			TCR2 Therapeutics Inc.
Date:	March 23, 2023		TCR2 Therapeutics Inc.
Date:	March 10, 2023	By:	/s/ Eric Sullivan
			By:	/s/ Eric Sullivan
			Eric Sullivan, Chief Financial Officer
				Eric Sullivan
				Chief Financial Officer

Filing Compare · TCR2 THERAPEUTICS INC.